AdAlta (1AD) 2018年年度报告「ASX」.pdf

1、FINANCIAL REPORTFOR THE YEAR ENDED 30 JUNE 2018ADALTA LTDABN 92 120 332 925CORPORATE DIRECTORYDIRECTORSDr Paul MacLemanMs Samantha CobbDr James WilliamsMs Elizabeth McCall Dr John ChiplinDr Robert PeachCOMPANY SECRETARYCameron JonesREGISTERED OFFICEUnit 152 Park DriveBundoora VIC 3083Telephone:+61 3

2、 9479 5159 Email:.auWebsite:.auSTOCK EXCHANGEAustralian Securities Exchange LimitedLevel 4,North Tower Rialto525 Collins StreetMelbourne VIC 3000ASX CODE1ADSHARE REGISTRYAutomic Registry Services Suite 310,Level 350 Holt StreetSurrey Hills NSW 2010Telephone:1300 288 664Website:.auAUDITORButler Setti

3、neri(Audit)Pty Ltd Unit 16,First Floor100 Railway RoadSubiaco WA 6008BANKERS Westpac Banking CorporationSOLICITORSLander&RogersLevel 12,600 Bourke StreetMelbourne VIC 3000AdAlta Limited Annual Report 20182CONTENTSDIRECTORS REPORT.6AUDITORS INDEPENDENCE DECLARATION.22CORPORATE GOVERNANCE STATEMENT.23

4、STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME.24STATEMENT OF FINANCIAL POSITION.25STATEMENT OF CHANGES IN EQUITY.26STATEMENT OF CASH FLOWS.27NOTES TO THE FINANCIAL STATEMENTS.28DIRECTORS DECLARATION.47INDEPENDENT AUDITORS REPORT.48SHAREHOLDER INFORMATION.53AdAlta Limited Annual Report 2

5、0183AdAlta Limited Annual Report 20184CHAIRMANS LETTERIt is my pleasure to open the financial year 2018 annual report looking back upon a year of notable achievements for AdAlta as we progress our new lead candidate to the clinic.During the year we made great advancement in demonstrating the strengt

6、h of the AdAlta drug development platform and the therapeutic potential of the i-body.Off the back of this effort,just after year end,we successfully completed a placement to institutional and sophisticated investors as well as a share purchase plan with existing shareholders raising$4.73 million fo